Regenxbio (RGNX) Current Assets (2014 - 2025)

Regenxbio's Current Assets history runs 12 years deep, the most recent figure standing at $281.3 million for Q4 2025.

• On a quarterly basis, Current Assets rose 1.18% year-over-year to $281.3 million in Q4 2025; TTM through Dec 2025 was $281.3 million, a 1.18% increase from a year earlier, with the FY2025 full-year figure at $281.3 million, up 1.18% from the prior year.
• Current Assets slipped to $281.3 million in Q4 2025 per RGNX's latest filing, from $332.0 million in the prior quarter.
• Across five years, Current Assets topped out at $518.8 million in Q4 2021 and bottomed at $278.0 million in Q4 2024.
• The 5-year median for Current Assets is $384.0 million (2023), against an average of $386.6 million.
• Across the five-year window, Current Assets surged 47.42% in 2021 and declined 20.78% in 2025, its largest moves.
• Year by year, Current Assets stood at $518.8 million in 2021, then declined by 19.82% to $416.0 million in 2022, then fell by 19.47% to $335.0 million in 2023, then decreased by 17.01% to $278.0 million in 2024, then rose by 1.18% to $281.3 million in 2025.
• Per Business Quant, the three latest RGNX Current Assets figures stand at $281.3 million (Q4 2025), $332.0 million (Q3 2025), and $373.8 million (Q2 2025).